MNPR Stock Price, Chart, Stats & News
MNPR chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -0.01% |
ROE | -0.06% |
D/E | 0.00x |
Interest coverage ratio | – |
MNPR valuation
P/E | – |
P/S | – |
P/B | 0.00x |
P/CF | -35.59x |
P/FCF | -33.38x |
P/OCF | -35.59x |
PEG | 0.96x |
EV multiple | -3096.04x |
About
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Similar securities
Based on sector and market capitalization
